Subscribe

Cervical Cancer

KEYNOTE-826: Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Pembrolizumab significantly improves PFS and OS in PD-L1–positive persistent, recurrent, or metastatic cervical cancer patients when added to standard chemotherapy, with or without bevacizumab, maintaining a manageable safety profile.

Adenoma Malignum

Mini-Tutorial on Adenoma Malignum

BEATcc: Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc)

EORTC-55994: Neoadjuvant Chemotherapy Followed by Surgery vs. Chemoradiation in Locally Advanced Cervical Cancer

EORTC and the trial from TATA memorial. Is neoadjuvant chemotherapy and surgery an alternative to chemoradiation in locally advanced cervical cancer?

DESTINY-PanTumor02

Phase II study evaluating the role of HER2-directed ADC Trastuzumab deruxtecan (T-DxD)

Para-aortic Lymph Node Dissection Prior to Radiation Therapy

Do we need to surgically remove para-aortic lymph nodes before radiation therapy?

OUTBACK Trial: Chemotherapy after Chemoradiation

OUTBACK trial

Pembrolizumab in Cervix Cancer

What is CPS, and how is it different from TPS?